About 84,120 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  28,769 results

LncRNA TGFB2-OT1 Promotes Progression and Angiogenesis in Hepatocellular Carcinoma by D...
Journal of Hepatocellular Carcinoma; Chen Y, Wu X et. al.

Mar 22nd, 2023 - Hepatocellular carcinoma (HCC) was the sixth most prevalent cancer worldwide. Long non-coding RNA TGFB2-OT1 has been proven to mediate inflammation and autophagy in vascular endothelial cells. However, its function in HCC is still unknown. We anal...

Liver Assessment in Patients with Ataxia-Telangiectasia: Transient Elastography Detects...
Canadian Journal of Gastroenterology & Hepatology; Donath H, Wölke S et. al.

Mar 22nd, 2023 - Ataxia-telangiectasia (A-T) is a rare autosomal-recessive multisystem disorder characterized by pronounced cerebellar ataxia, telangiectasia, cancer predisposition, and altered body composition. Liver diseases with steatosis, fibrosis, and hepatoc...

Association between posttreatment α-fetoprotein reduction and outcomes in real-world US...
Cancer Abou-Alfa GK, Wang X et. al.

Mar 22nd, 2023 - Clinical trials suggest α-fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real-world settings is unclear. Patients with advanced hepato...

A case of hemoperitoneum after percutaneous radiofrequency ablation in a patient with h...
Forensic Science, Medicine, and Pathology; Ishigami A, Inaka S et. al.

Mar 22nd, 2023 - We report a case of hemoperitoneum after percutaneous radiofrequency ablation in a patient with hepatocellular carcinoma. A 60-year-old female was hospitalized for the treatment of thrombasthenia and cirrhosis caused by chronic Hepatitis C, and co...

plenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma...
Journal of Gastroenterology; Gao TM, Zhou J et. al.

Mar 22nd, 2023 - Liver cirrhosis is the highest risk factor for hepatocellular carcinoma (HCC) worldwide. However, etiological therapy is the only option in cirrhosis patients to decrease the HCC risk. The aim of this study was to explore whether laparoscopic sple...

see more →

Guidelines  42 results

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or adv...
PloS One; Gaugain L, Cawston H et. al.

Jan 19th, 2023 - The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment...

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: E...
Gastroenterology Wang B, Bonkovsky HL et. al.

Jan 16th, 2023 - The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase. Ac...

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.
Clinical and Molecular Hepatology;

Oct 21st, 2022 - Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelin...

AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Dise...
Gastroenterology Long MT, Noureddin M et. al.

Jul 17th, 2022 - Nonalcoholic fatty liver disease (NAFLD) is well recognized as a leading etiology for chronic liver disease, affecting >25% of the US and global populations. Up to 1 in 4 individuals with NAFLD have nonalcoholic steatohepatitis, which is associate...

EASL Clinical Practice Guidelines on haemochromatosis.
Journal of Hepatology; ,

Jun 7th, 2022 - Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropa...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  2,373 results

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)

Mar 10th, 2023 - Selective Internal Radiation Therapy (SIRT) is a technique where radiation is internally delivered to a tumor. In SIRT, small radioactive beads are deposited in the liver through a large blood vessel (hepatic artery). SIRT that uses the radioactiv...

Ate-Bev Early Response Prediction Model in Advanced HCC

Mar 10th, 2023 - The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocell...

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Mar 10th, 2023 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of tegavivint administered as an intravenous (IV) infusion over 4 hours, once weekly for 3 weeks, followed by a 1 week rest, in a 28-day cyc...

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Mar 10th, 2023 - The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not re...

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To investigate the confirmed objective response rate (ORR) of nivolumab and ipilimumab in patients with hepatocellular carcinoma (HCC) who have progressed radiographically on atezolizumab/bevacizumab that necessitates change ...

see more →

News  2,422 results

An earlier hep B biomarker for clinical outcomes?
Jim Kling, MDedge News

Mar 8th, 2023 - Low serum levels of the hepatitis B core-related antigen (HBcrAg) could be an early biomarker of a functional cure of a hepatitis B infection, according to new findings from a retrospective study. A drop in HBcrAg predicted the seroclearance of he.

Adding SBRT to sorafenib boosts survival in liver cancer
Roxanne Nelson, RN, BSN

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved bo.

Pigmentary disorder experts welcome research explosion
Tom Collins

Jan 25th, 2023 - ORLANDO – Research on pigmentary disorders has entered an overdue era of increased attention, resulting in more treatment options and the promise of improved quality of life for patients, a panel of experts said in a session on this topic at the O.

Palliative radiotherapy successfully reduces end-stage liver cancer pain
Randy Dotinga

Jan 25th, 2023 - Most patients with end-stage hepatocellular carcinoma experience pain, but when it’s severe, how best to control the pain is debatable. A number of studies, including one recently presented at the ASCO Gastrointestinal Cancers Symposium 2023, show.

Uterine Cancer Recognized as 9/11-Related; Working With Cancer; Post-Dx Suicide Risk

Jan 20th, 2023 - The CDC added uterine cancer to the list of covered World Trade Center-related conditions; women enrolled in the World Trade Center Health Program will have access to cancer care and treatment if their uterine cancer is related to 9/11 exposures. ...

see more →

Patient Education  11 results see all →